Why Value-Based Care Has Struggled in Oncology
Value-based care (VBC) promised to transform oncology — better outcomes, lower costs, and smarter resource use. Yet, time and again, these promises have gone unfulfilled. Major federal programs such as the Oncology Care Model (OCM) and the Enhancing Oncology Model (EOM) from the Center for Medicare and Medicaid Innovation failed to deliver the expected benefits. The oncology community, despite tremendous effort, could not reliably show improved patient outcomes while simultaneously reducing costs.
The reasons are complex. Payer-initiated VBC programs require substantial ongoing management. Payers must design oncology models and then rely on individual practices to participate — an approach that limits total population impact and creates inconsistency. Additionally, small patient sample sizes make shared savings calculations unreliable. These structural flaws, combined with fragmented care coordination, have consistently undermined even well-intentioned VBC efforts.
However, Thyme Care has found a way forward. Moreover, its model addresses the very root causes that caused previous programs to fail.
What Makes Thyme Care Different
A Population-First Approach
Thyme Care takes a fundamentally different stance. Rather than waiting for individual practices to opt into programs, Thyme Care covers all patients for a given payer — regardless of location or treating physician. This means every patient in its at-risk population gains access to a robust care management platform. By aggregating downside risk across an entire population, the model reduces variation from small sample sizes. Consequently, shared savings calculations become far more accurate.
Technology at the Core
Thyme Care’s proprietary platform, Thyme Box, sorts real-time data from payers, electronic health records (EHRs), and clinical systems. It then recommends personalized interventions for each patient. Furthermore, Thyme Care Signal processes electronic patient-reported outcomes (ePROs) to detect warning signs before they escalate. This proactive, data-driven approach represents a major departure from the reactive, episodic care that traditional oncology models rely upon.
ePRO-Driven Monitoring: Catching Problems Early
How ePRO Monitoring Works
Electronic patient-reported outcomes allow patients to regularly report symptoms between clinic visits. Thyme Care’s clinical team then reviews these reports in real time. When a concern surfaces, the team intervenes — scheduling urgent evaluations, coordinating follow-up care, or connecting patients with supportive services. This system effectively bridges the dangerous gap between scheduled appointments.
Why Early Intervention Matters
In traditional oncology care, patients often wait until symptoms become severe before seeking help. That delay typically leads to emergency department (ED) visits, hospital admissions, and costly readmissions. Thyme Care’s model specifically targets this pattern. Through timely outreach and coordinated follow-up, the company prevents complications from compounding — protecting both patient health and health plan budgets.
Practice Partnerships That Actually Work
Working With Oncologists, Not Around Them
A key reason past VBC models failed is that they positioned payers against practices. Thyme Care takes the opposite approach. The company builds deep partnerships with more than 1,400 oncologists nationwide. These partnerships allow Thyme Care to serve as an extension of the practice — handling between-visit patient burden, managing ePRO data, and surfacing clinical intervention opportunities.
Supporting Therapeutic Innovation
Beyond care navigation, Thyme Care actively supports therapeutic interchange initiatives. These include biosimilar adoption programs, which can significantly reduce drug spend without compromising clinical outcomes. The company’s clinical team surfaces prescribing recommendations collaboratively with partner practices. Importantly, the practice always retains final authority over clinical decisions. This light-touch model builds trust and drives sustained participation.
Simplifying Oncology VBC for Payers
One Accountable Entity, Total Population Coverage
For payers, managing an oncology VBC program in-house is administratively demanding. Thyme Care eliminates much of that burden. By serving as a single accountable entity covering all attributed patients, the company allows payers to access consistent, population-wide care management without building complex internal programs.
Aggregating Risk for Better Accuracy
Small patient populations produce noisy shared savings data. When Thyme Care aggregates downside risk across all payer-attributed patients, the denominator grows substantially. As a result, performance metrics become more reliable and actionable. Payers gain a cleaner view of ROI. Additionally, the administrative burden of tracking individual practice participation disappears entirely.
Measurable Results That Drive Real Savings
Thyme Care’s model is not theoretical — it delivers concrete, documented outcomes:
- 28% relative risk reduction in ED visits or inpatient admissions among patients who completed Thyme Care’s ePRO program.
- 83% of patients discharged from hospital had a coordinated follow-up visit scheduled within days of discharge.
- 30% relative risk reduction in readmissions among complex patients enrolled in Thyme Care’s readmission prevention program.
These figures represent significant savings for health plan partners. More importantly, they represent better experiences and outcomes for patients facing one of the most difficult diagnoses a person can receive.
The Road Ahead for Value-Based Cancer Care
Building on Proven Foundations
VBC in oncology may be under political and financial pressure. Nevertheless, the urgency behind this work has not diminished. Thyme Care continues to expand its reach — currently partnering with more than 1,400 oncologists — while actively managing over half a billion dollars in medical spend across its risk-based contracts.
A Model Others Can Learn From
The lessons from Thyme Care are clear. Focusing on all patients — not just high-risk outliers — produces better population-level outcomes. Working with oncologists as partners, rather than compliance targets, drives sustained clinical engagement. Ensuring that savings flow back to payers creates a financially self-sustaining model. Together, these principles form a replicable blueprint for value-based cancer care that actually works.
